SGLT2抑制剂在冠心病中的作用机制的研究进展

Research progress on pharmacological effects and relevant mechanism of SGLT2 inhibitors in coronary heart disease

摘要:

钠-葡萄糖协同转运蛋白2抑制剂（sodium-dependent glucose transporters 2 inhibitors, SGLT2i）被广泛应用于降糖治疗，并且已被推荐为Ⅰ类药物治疗心力衰竭。然而，SGLT2i在冠心病中的作用和机制尚无准确定论。本文概述了SGLT2i在冠心病中的药理作用和相关机制，特别是其改善血管内皮功能的作用；同时讨论了相关研究的局限性和未来的研究方向。该综述对SGLT2i在冠心病中的研究提供了新的思路和参考，对于临床应用和科研方向具有重要意义。

Abstract:

Sodium-dependent glucose transporter 2 inhibitors(SGLT2i) have been widely used for glucose-lowering therapy andalso recommended as a class Ⅰ medication for treating heart failure. However, the exact effects and mechanisms of SGLT2i in coronary heart disease(CHD) are still not fully understood. This review summarizes the pharmacological effects and relevant mechanisms of SGLT2i in CHD, particularly for improving vascular endothelial function; and also discusses limitations of related studies and future research directions.